DOI QR코드

DOI QR Code

In Vivo Evaluation of Curcumin-loaded Nanoparticles in a A549 Xenograft Mice Model

  • Yin, Hai-Tao (Department of Radiotherapy, the Central Hospital of Xuzhou, Affiliated Hospital of Southeast University) ;
  • Zhang, De-Geng (Department of Oncology, Jiangsu Taizhou People's Hospital) ;
  • Wu, Xiao-Li (Department of Women Health Care, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University) ;
  • Huang, Xin-En (Department of Chemotherapy, JiangSu Cancer Hospital and Research Institute) ;
  • Chen, Gang (Department of Oncology, the Affiliated Jiangning Hospital of Nanjing Medical University)
  • Published : 2013.01.31

Abstract

Curcumin (Cum) has been reported to have potential chemo-preventive and chemotherapeutic activity through influencing various processes, inducing cell cycle arrest, differentiation and apoptosis in a series of cancers. However, the poor solubility of Cum limits its further applications in the treatment of cancer. We have previously reported Cum-loaded nanoparticles (Cum-NPs) prepared with amphilic methoxy poly(ethylene glycol)-polycaprolactone (mPEG-PCL) block copolymers. The current study demonstrated superior antitumor efficacy of Cum-NPs over free Cum in the treatment of lung cancer. In vivo evaluation further demonstrated superior anticancer effects of Cum-NPs by delaying tumor growth compared to free Cum in an established A549 transplanted mice model. Moreover, Cum-NPs showed little toxicity to normal tissues including bone marrow, liver and kidney at a therapeutic dose. These results suggest that Cum-NPs are effective to inhibit the growth of human lung cancer with little toxicity to normal tissues, and could provide a clinically useful therapeutic regimen. They thus merit more research to evaluate the feasibility of clinical application.

References

  1. Zhang LQ, Huang XE, Wang J, (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
  2. Zhang XZ, Huang XE, Xu YL, et al (2012). Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8. https://doi.org/10.7314/APJCP.2012.13.5.2415
  3. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
  4. Yu B, Tai HC, Xue W, et al (2010). Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol, 27, 286-98. https://doi.org/10.3109/09687688.2010.521200
  5. Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40. https://doi.org/10.7314/APJCP.2012.13.5.2339
  6. Rothdiener M, Beuttler J, Messerschmidt SK, et al (2010). Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes. Methods Mol Biol, 624, 295-308. https://doi.org/10.1007/978-1-60761-609-2_20
  7. Shu J, Li CG, Liu YC, et al (2012).Comparison of Serum Tumor Associated Material (TAM) with Conventional Biomarkers in Cancer Patients. Asian Pac J Cancer Prev, 13, 2399-403. https://doi.org/10.7314/APJCP.2012.13.5.2399
  8. Surh YJ, Chun KS, Cha HH, et al (2001). Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res, 1, 480-1.
  9. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  10. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of $Endostar^{(R)}$ combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  11. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
  12. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54. https://doi.org/10.7314/APJCP.2012.13.5.2349
  13. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
  14. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
  15. Yin H, Zhang H, Liu B (In press). Superior Anticancer Efficacy of Curcumin-Loaded Nanoparticles Against Lung Cancer. Acta Biochim Biophys Sin.
  16. Aggarwal BB, Kumar A, Bharti AC (2003). Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res, 23, 363-98.
  17. Aggarwal BB, Sung B (2009). Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci, 30, 85-94. https://doi.org/10.1016/j.tips.2008.11.002
  18. Hossain M, Banik NL, Ray SK (2012). Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int, 61, 1102-13. https://doi.org/10.1016/j.neuint.2012.08.002
  19. Hosta-Rigau L, Olmedo I, Arbiol J, et al (2010). Multifunctionalized gold nanoparticles with peptides targeted to gastrin-releasing peptide receptor of a tumor cell line. Bioconjug Chem, 21, 1070-8. https://doi.org/10.1021/bc1000164
  20. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
  21. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  22. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy.Asian Pac J Cancer Prev, 11, 1059-62.
  23. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of $OxyContin^{(R)}$ administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  24. Li CG, Huang XE, Li Y, et al (2011). Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer. Asian Pac J Cancer Prev, 12, 487-90.
  25. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  26. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
  27. Liu S, Yang H, Wan L, et al (2013). Penetratin-mediated delivery enhances the antitumor activity of the cationic antimicrobial peptide magainin II. Cancer Biother Radiopharm, Jan 3. [Epub ahead of print]
  28. Liu Wei, Li Suyi, Huang Xinen, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. https://doi.org/10.7314/APJCP.2012.13.5.2409
  29. Pan MH, Lin-Shiau SY, Lin JK (2000). Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IKappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol, 60, 1665-76. https://doi.org/10.1016/S0006-2952(00)00489-5
  30. Phillips JM, Clark C, Herman-Ferdinandez L, et al (2011). Curcumin inhibits skin squamous cell carcinoma tumor growth in vivo. Otolaryngol Head Neck Surg, 145, 58-63. https://doi.org/10.1177/0194599811400711
  31. Rocks N, Bekaert S, Coia I, et al (2012). Curcumin-cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer. Br J Cancer, 107, 1083-92. https://doi.org/10.1038/bjc.2012.379
  32. Almansour NM, Pirogova E, Coloe PJ, et al (2012). Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study. Future Med Chem, 4, 1553-65. https://doi.org/10.4155/fmc.12.98
  33. Cutler CS, Chanda N, Shukla R, et al (2013). Nanoparticles and phage display selected peptides for imaging and therapy of cancer. Recent Results Cancer Res, 194, 133-47. https://doi.org/10.1007/978-3-642-27994-2_8
  34. Duvoix A, Blasius R, Delhalle S, et al (2005). Chemopreventive and therapeutic effects of curcumin. Cancer Lett, 223, 181-90. https://doi.org/10.1016/j.canlet.2004.09.041
  35. EI-Azab M, Hishe H, Moustofa Y, et a1 (2011). Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice. Eur J Pharmacol, 652, 7-14. https://doi.org/10.1016/j.ejphar.2010.11.008
  36. Franzen S (2011). A comparison of pettide and folate receptor targeting of cancer cells: from single agent to nanoparticle. Expert Opin Drug Deliv, 8, 281-98. https://doi.org/10.1517/17425247.2011.554816
  37. Ganta S, Amiji M (2009). Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm, 6, 928-39. https://doi.org/10.1021/mp800240j
  38. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  39. Gong P, Huang XE, Chen CY, et al (2012). Comparison of complications of peripherally inserted central catheters with ultrasound guidance or conventional methods in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5. https://doi.org/10.7314/APJCP.2012.13.5.1873
  40. Guo H, Lu J, Hathaway H, et al (2011). Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides. Bioconjug Chem, 22, 1682-9. https://doi.org/10.1021/bc200252j

Cited by

  1. Role of MYH Polymorphisms in Sporadic Colorectal Cancer in China: A Case-control, Population-based Study vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6403
  2. Colorectal Cancer Screening in High-risk Populations: a Survey of Cognition among Medical Professionals in Jiangsu, China vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6487
  3. Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6663
  4. Helicobacter pylori Infection and the Risk of Colorectal Adenoma and Adenocarcinoma: an Updated Meta-analysis of Different Testing Methods vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7613
  5. In vitro and in vivo Evaluation of the Antitumor Efficiency of Resveratrol Against Lung Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.1703
  6. Phase II Study on Pemetrexed-based Chemotherapy in Treating Patients with Metastatic Gastric Cancer not Responding to Prior Palliative Chemotherapy vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2703
  7. Phase II Study on Breast Conservative Surgery Plus Chemo- and Radiotherapy in Treating Chinese Patients with Early Staged Breast Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3747
  8. Potential Therapeutic Efficacy of Curcumin in Liver Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3855
  9. Hsa-miR-181a-5p Expression and Effects on Cell Proliferation in Gastric Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3871
  10. Combined Effects of Curcumin and Triptolide on an Ovarian Cancer Cell Line vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4267
  11. Risk Assessment on Anastomotic Leakage after Rectal Cancer Surgery: An Analysis of 753 Patients vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4447
  12. ) Combined with Chemotherapy in Treating Patients with Advanced Lung Adenocarcinoma vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4791
  13. Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4801
  14. Acidic Pelvic Drainage as a Predictive Factor For Anastomotic Leakage after Surgery for Patients with Rectal Cancer vol.14, pp.9, 2013, https://doi.org/10.7314/APJCP.2013.14.9.5441
  15. Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells vol.43, pp.4, 2013, https://doi.org/10.3892/ijo.2013.2050
  16. Curcumin-loaded nanoparticles enhance apoptotic cell death of U2OS human osteosarcoma cells through the Akt-Bad signaling pathway vol.44, pp.1, 2013, https://doi.org/10.3892/ijo.2013.2175
  17. Novel antitumor mechanisms of curcumin: implication of altered tumor metabolism, reconstituted tumor microenvironment and augmented myelopoiesis vol.13, pp.3, 2014, https://doi.org/10.1007/s11101-014-9364-2
  18. Cytotoxic Activity of Biosynthesized Gold Nanoparticles with an Extract of the Red Seaweed Corallina officinalis on the MCF-7 Human Breast Cancer Cell Line vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4311
  19. Application of Biosynthesized Silver Nanoparticles Against a Cancer Promoter Cyanobacterium, Microcystis aeruginosa vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6773
  20. Comparison of Inhibitory Effects of 17-AAG Nanoparticles and Free 17-AAG on HSP90 Gene Expression in Breast Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7113
  21. Preparation of 5-fluorouracil-loaded Nanoparticles and Study of Interaction with Gastric Cancer Cells vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7611
  22. Reversal of Resistance towards Cisplatin by Curcumin in Cervical Cancer Cells vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1403
  23. Curcumin Inhibits Expression of Inhibitor of DNA Binding 1 in PC3 Cells and Xenografts vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1465
  24. v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2221
  25. Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3581
  26. Targeting Cancer with Nano-Bullets: Curcumin, EGCG, Resveratrol and Quercetin on Flying Carpets vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3865
  27. Passively Targeted Curcumin-Loaded PEGylated PLGA Nanocapsules for Colon Cancer Therapy In Vivo vol.11, pp.36, 2015, https://doi.org/10.1002/smll.201403799
  28. Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10281
  29. Nanoparticles Promise New Methods to Boost Oncology Outcomes in Breast Cancer vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1683
  30. Preparation and Evaluation of Chrysin Encapsulated in PLGA-PEG Nanoparticles in the T47-D Breast Cancer Cell Line vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3753
  31. Preparation, characterization, in vitro release, and pharmacokinetic studies of curcumin-loaded mPEG–PVL nanoparticles vol.72, pp.1, 2015, https://doi.org/10.1007/s00289-014-1260-9
  32. Biosynthesized Platinum Nanoparticles Inhibit the Proliferation of Human Lung-Cancer Cells in vitro and Delay the Growth of a Human Lung-Tumor Xenograft in vivo vol.19, pp.2, 2016, https://doi.org/10.3831/KPI.2016.19.012
  33. Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art vol.24, pp.4, 2016, https://doi.org/10.3109/1061186X.2015.1055570
  34. Enhanced Radiosensitization Effect of Curcumin Delivered by PVP-PCL Nanoparticle in Lung Cancer vol.2017, pp.1687-4129, 2017, https://doi.org/10.1155/2017/9625909
  35. Nanoengineered strategies to optimize dendritic cells for gastrointestinal tumor immunotherapy: from biology to translational medicine vol.9, pp.14, 2014, https://doi.org/10.2217/nnm.14.115
  36. Nanoscale modification of chrysin for improved of therapeutic efficiency and cytotoxicity pp.2169-141X, 2018, https://doi.org/10.1080/21691401.2018.1434661
  37. Evidence of curcumin and curcumin analogue effects in skin diseases: A narrative review vol.234, pp.2, 2018, https://doi.org/10.1002/jcp.27096
  38. Poly-ε-caprolactone (PCL), a promising polymer for pharmaceutical and biomedical applications: Focus on nanomedicine in cancer pp.1563-535X, 2019, https://doi.org/10.1080/00914037.2018.1539990